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Abstract 
Cathepsin A (CTSA) is a multifunctional lysosomal enzyme, and 
its hereditary defect causes an autosomal recessive disorder called 
galactosialidosis.  In a certain number of galactosialidosis patients, 
a base substitution from adenine to guanine is observed at the +3 position 
of the 7th intron (IVS7 +3a>g) of the CTSA gene.  With this mutation, 
a splicing error occurs; and consequently mRNA lacking the 7th exon is 
produced.  This skipping of exon 7 causes a frame shift of the transcripts, 
resulting in a non-functional CTSA protein and hence galactosialidosis.  
This mutation seems to make the interaction between the 5’-splice site 
of intron 7 of pre-mRNA and U1 small nuclear RNA (U1 snRNA) much weaker.  
In the present study, to produce properly spliced mRNA from the CTSA 
gene harboring this IVS7 +3a>g mutation, we examined the possible 
usefulness of modified U1 snRNA that could interact with the mutated 
5’-splice site.  Toward this goal, we first prepared a model system using 
a mutant CTSA mini gene plasmid for delivery into HeLa cells.  Then, 
we examined the effectiveness of modified U1 snRNA on the formation of 
properly spliced mRNA from this mutant CTSA mini gene.  As a result, 
we succeeded in obtaining improved formation of properly spliced CTSA 
mRNA.  Our results suggest the usefulness of modified U1 snRNA for rescue 
from exon 7 skipping caused by the IVS7 +3a>g mutation of the CTSA gene. 
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1. Introduction 
In the various processes involved in eukaryotic gene expression, 
the splicing of nuclear mRNA precursor (pre-mRNA) is one of the critical 
steps of RNA processing.  During this splicing process, introns are 
precisely excised at the exon/intron boundaries, and adjacent exons are 
joined together to form the mature mRNA.  This splicing reaction is 
initiated by the association of U1 small nuclear RNA (U1 snRNA) with 
the 5’-splice site (ss) of pre-mRNA [Krämer et al., 1984; Zhuang and 
Weiner, 1986; Roca et al., 2013].  In general, the third to eleventh 
bases of U1 snRNA (5’-ACUUACCUG) bind to the 5’-ss of pre-mRNA by RNA-RNA 
base paring.  The consensus sequence of the 5’-ss was reported to be 
5’-MAG/GURAGU, with “/” indicating the boundary between exon and intron, 
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and “M” and “R” representing A or C and A or G, respectively [Mount, 
1982].  In many cases, however, the nucleotide sequences of the 5’-ss 
do not completely match with the above consensus sequence.  Even though 
not completely conserved, such a 5’-ss can be recognized by U1 snRNA, 
and the splicing reaction is initiated.  However, if the degree of 
conservation of the 5’-ss is too low, the association of U1 snRNA with 
pre-mRNA does not properly occur, and a splice defect can thus be induced 
[Faustino and Cooper, 2003; Wang and Cooper, 2007; Havens et al., 2013]. 
Cathepsin A (EC 3.4.16.5), hereafter abbreviated as CTSA, is a 
multifunctional lysosomal enzyme showing the catalytic activities of 
deamidase, esterase, and carboxypeptidase.  In addition, this enzyme 
is essential for the stabilization of β-galactosidase and the activation 
of neuraminidase.  Therefore, a genetic defect of CTSA causes a 
significant decrease in the activities of β-galactosidase and 
neuraminidase, resulting in an autosomal recessive lysosomal storage 
disorder called galactosialidosis [Shimmoto et al., 1993; Hiraiwa, 1999; 
Ketterer et al., 2017].  About 80 patients with galactosialidosis have 
been reported globally.  Based on the age of onset and severity of their 
symptoms, patients are classified as early infantile type, late 
infantile type, or juvenile/adult type.  More than 60% of these patients 
have been reported in Japan, and most of them are of the juvenile/adult 
type [Hossain et al., 2016].   
The gene for human CTSA is located on 20q13.1 [Wiegant et al., 
1991].  It consists of 15 exons (one 5’-non-coding exon and 14 coding 
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exons) spanning approx. 7.5 kilobase pairs (kbp) and encodes a 480 amino 
acid-inactive precursor protein [Shimmoto et al., 1996].  In the human 
CTSA gene, more than 10 missense mutations have been reported to cause 
galactosialidosis [OMIM®, 2009].  In addition, an adenine to guanine 
base substitution at the +3 position of the 7th intron 
(NG_008291.1:g.7363A>G) is frequently found in juvenile/adult-type 
Japanese galactosialidosis patients (homozygous for this mutation or 
heterozygous with the other allele being a missense mutation) [Shimmoto 
et al., 1990, 1993].  In this manuscript, this mutation is referred to 
as IVS7 +3a>g.  With such a mutation, mature mRNA lacking the 7th exon 
(SpDEx7) is formed.  Skipping of the 7th exon causes a frame shift in 
the transcripts, and thus functional mature CTSA protein is not produced.  
As a result, the IVS7 +3a>g mutation of the CTSA gene causes 
galactosialidosis.  As treatment for galactosialidosis, 
transplantation of cells overexpressing human CTSA [Zhou et al., 1995; 
Hahn et al., 1998] and enzyme replacement therapy [Itoh et al., 2016] 
are currently being investigated.  In addition, the injection of a 
recombinant adeno-associated virus (rAAV) vector expressing human CTSA 
under the control of a liver-specific promoter was reported to be 
effective for galactosialidosis treatment of CTSA-deficient mouse [Hu 
et al., 2012]; and a low-molecular-weight chemical chaperone was 
reported to increase the endogenous β-galactosidase activity in 
CTSA-deficient cells [Hossain et al., 2016].  However, for the 
development of new therapies for human galactosialidosis, a novel 
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approach for treatment of this disorder is necessary.   
In the IVS7 +3a>g mutation of the CTSA gene, it is predicted that 
U1 snRNA cannot interact with the 5’-ss of the 7th intron of the pre-mRNA; 
and, hence, skipping of the 7th exon occurs.  To negate the splice defect 
caused by the 5’-ss mutation, the application of a U1 snRNA of which 
its 5’-end was modified to enable association with the mutated 5’-ss 
was reported [Havens et al., 2013].  In the present study, we constructed 
a model experimental system using a CTSA mini gene harboring the IVS7 
+3a>g mutation and examined possible modified U1 snRNA-mediated rescue 
from the splice defect of the human CTSA gene caused by this mutation. 
 
2. Materials and methods 
2.1. Construction of expression plasmids encoding U1 snRNAs 
All recombinant DNA experiments were performed according to the 
guidelines of Tokushima University. 
A genomic DNA fragment encoding the human U1 snRNA gene (accession 
number V00591), from its own promoter to the transcription termination 
signal, i.e., nucleotide sequence from -393 to +199 (nucleotide sequence 
numbered taking the 5’-end of mature U1 snRNA as +1) [Murphy et al., 
1982], was prepared from human genomic DNA (Clontech, Palo Alto, CA, 
USA) by use of the polymerase chain reaction (PCR).  The obtained DNA 
fragment was subcloned into pUC19.  In this paper, the expression plasmid 
encoding wild-type U1 snRNA is referred to as the wild-type U1 plasmid.  
The expression plasmids of modified U1 snRNA were prepared by PCR using 
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mutated oligonucleotide primers and the wild-type U1 plasmid as a 
template.  Details of the plasmid construction are summarized in 
Supplemental methods. 
 
2.2. Construction of CTSA mini gene plasmids 
Genomic DNA fragments encoding the human CTSA gene (accession 
number NG_008291.1) were isolated by PCR using human genomic DNA 
(Clontech) as a template.  Two regions, from exon 6 to exon 8, and from 
exon 3 to exon 11, were amplified with the primer pairs of primer 6 (sense) 
and primer 8 (antisense), and primer 3 (sense) and primer 11 (antisense), 
respectively.  The obtained DNA fragment was subcloned into 
pcDNA3.1/Hygro(-) mammalian expression plasmid (Invitrogen, Carlsbad, 
CA, USA), in which DNA fragment encoding CTSA was sandwiched between 
those encoding enhanced green fluorescent protein (EGFP, Clontech) and 
c-Myc tag.  These mini gene plasmids enabling transcription of the 
pre-mRNA of parts of the CTSA gene are referred to as wild-type CTSA 
mini gene plasmids (“exons 6-8” or “exons 3-11”).   Details of the 
plasmid construction are summarized in Supplemental methods and 
Supplemental results Fig.S1A.   
For construction of the CTSA mini gene plasmid harboring the IVS7 
+3a>g mutation, the overlap extension PCR method was carried out with 
mutated oligonucleotide primers [Ho et al., 1989] using a wild-type CTSA 
mini gene plasmid as a template.  The plasmids including the mutation 
were referred to as mutant CTSA mini gene plasmids (“exons 6-8” or “exons 
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3-11”).  The detailed nucleotide sequence of CTSA mini gene plasmid 
(exons 3-11) is shown in Supplemental results Fig.S1B and C.   
 
2.3. Cell culture and transfection 
HeLa cells were cultured in Minimum Essential Medium 
(Sigma-Aldrich, St. Louis, MO, USA) containing 10% fetal bovine serum 
(MP Biomedicals, Santa Ana, CA, USA) and 1% MEM Non-essential Amino Acids 
(Sigma-Aldrich).  COS7 cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (Sigma-Aldrich) containing 10% fetal bovine serum.  
Eighteen to 24 hrs before transfection, 3.5 x 105 cells were suspended 
in 2 mL of culture medium and plated in each well of a 6-well plate.   
For RNA analysis (HeLa cells), basically, a 1-μg aliquot of the 
CTSA mini gene plasmid and a 2-μg aliquot of U1 plasmid were mixed with 
3 μL of X-treme GENE HP (Roche Diagnostics, Indianapolis, IN, USA) in 
100 μL/well Opti-MEM (Invitrogen) and added to each culture well.  For 
protein analysis (COS7 cells), a 2-μg aliquot of the CTSA mini gene 
plasmid, a 1-μg aliquot of U1 plasmid, and a 0.3-μg aliquot of EGFP 
expression plasmid (only EGFP-coding region was inserted into 
pcDNA3.1/Hygro(-) plasmid) were mixed with 5 μL of Lipofectamine 2000 
(Invitrogen) in 500 μL/well Opti-MEM and added to each well.   
After incubation for 24 hrs, total RNA was prepared from HeLa 
cells by use of an RNeasy Plus Kit (QIAGEN, Hilden, Germany) or ISOGEN 
II (Nippon Gene, Tokyo, Japan) according to the methods recommended by 
the suppliers.  For protein analysis, COS7 cells were dissolved in RIPA 
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buffer (Nacalai Tesque, Kyoto, Japan) supplemented with 0.1% sodium 
dodecyl sulfate (SDS), and their lysates were prepared.   
 
2.4. Reverse transcription-PCR (RT-PCR) 
To obtain single-stranded complementary DNA (ss-cDNA), total RNA 
from HeLa cells was reversely transcribed with oligo(dT) primer.  For 
specific amplification of the transcripts derived from the CTSA mini 
gene plasmid, ss-cDNA was amplified by 2 rounds of PCR.  Briefly, ss-cDNA 
corresponding to the region sandwiched between the T7 promoter and BGH 
polyadenylation signal region of the pcDNA3.1/Hygro(-) plasmid was first 
amplified by using the primer pair of T7 primer (sense) and BGH pA primer 
(antisense).  Then, the reaction mixture was diluted with distilled 
water.  To obtain the complementary DNA (cDNA) fragment corresponding 
to the region from exon 6 to exon 8 of the human CTSA gene, we amplified 
a diluted reaction mixture by using the primer pair of primer 6 and primer 
8.  The reaction mixtures of second PCR were subjected to polyacrylamide 
gel electrophoresis (PAGE) with DNA size marker (pUC19 digested with 
MspI).  The gel was stained with ethidium bromide and visualized by use 
of an LAS500 (Fujifilm, Tokyo, Japan).  The band intensity was quantified 
with Multi Gauge 3.2 (Fujifilm), and the degree (%) of exon 7 inclusion 
was expressed as the mean ± standard deviation (SD) from at least 3 
different transfection experiments.   
As a check for the transcripts in normal human cells, samples 
of poly(A)+ RNA of human liver (Clontech) and total RNA of HeLa cells 
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were reversely transcribed with oligo(dT) primer, and the cDNA fragment 
corresponding to the region from exon 6 to exon 8 of the human CTSA gene 
was amplified by using the primer pair of primer 6 and primer 8.  Details 
are summarized in Supplemental methods.   
 
2.5. Western blot analysis 
SDS–PAGE and Western blot analysis were carried out as described 
previously [Matsuo et al., 2010], using lysates of COS7 cells transfected 
with plasmids.  The protein concentration of the lysate was measured 
with a BCA protein assay kit (Thermo Scientific, Rockford, IL, USA) using 
bovine serum albumin as the standard protein.  A 20-μg protein sample 
was mixed with an equal volume of 2×SDS-sample buffer and then loaded 
onto a 10% polyacrylamide gel with WIDE-VIEW Pre-stained Protein Size 
Marker III (Wako Pure Chemical Industries, Osaka, Japan).  Proteins in 
the gel were transferred onto a nitrocellulose membrane (GE Healthcare, 
Buckinghamshire, England), after which the membrane was incubated in 
Tris-buffered saline supplemented with 0.05% Tween-20, 3% nonfat dry 
milk, and anti-EGFP antibody (MBL, Nagoya, Japan) or anti-Myc tag 
antibody (Cell Signaling Technology, Danvers, MA, USA).  To detect 
anti-EGFP or anti-Myc tag antibodies on the membrane, anti-rabbit IgG 
(Cell Signaling Technology) or anti-mouse IgG (Sigma-Aldrich) 
conjugated with horse radish peroxidase, respectively, were used.  The 
immunoreactive signals were visualized by use of the ECL detection system 
(GE Healthcare) and LAS500.   
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2.6. Calculation of the splice site score 
Splice site score of the 5’-ss of intron 7 of the CTSA gene was 
calculated using splice site prediction programs; Human Splicing Finder 
[Desmet et al., 2009] (http://www.umd.be/HSF3/), MaxEntScan [Yeo and 
Burge, 2004] (http://www.umd.be/HSF3/), NNSPLICE 0.9 [Reese et al. , 
1997] (http://www.fruitfly.org/seq_tools/splice.html). 
 
3. Results 
3.1. Construction of model system mimicking the IVS7 +3a>g mutation of 
the CTSA gene  
The nucleotide sequence of the 5’-end of wild-type U1 snRNA and 
those of the 5’-ss of intron 7 of CTSA pre-mRNAs are depicted in Fig. 
1A.  As mentioned, in general, the third to eleventh bases of the 
wild-type U1 snRNA bind to the 5’-ss of pre-mRNA.  The 5’-ss of the intron 
7 of pre-mRNA transcribed from the wild-type CTSA gene has 2 nucleotides 
non-complementary with the 5’-end of U1 snRNA.  Nevertheless, it seems 
to be properly recognized by wild-type U1 snRNA.  This interpretation 
was supported by our experimental results: when we examined whether the 
transcript encoded by the wild-type CTSA gene was precisely spliced in 
human healthy tissue (liver) and HeLa cells, almost all transcripts were 
found to be correctly spliced in a manner containing exon 7 (“exons 6-8”) 
as clearly demonstrated in Fig. 1B.  Although a faint band indicating 
the skipping of exon 7 was observed in the sample of HeLa cells (“exon 
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6 and exon 8”), its level was far from that of the ordinary transcript.  
We do not have any information as to how it was formed.  On the contrary, 
in the case of the IVS7 +3a>g mutation, the 5’-ss of intron 7 of pre-mRNA 
has 3 nucleotides non-complementary with the 5’-end of U1 snRNA.  Thus, 
this mutation is thought to cause a splice defect at this exon/intron 
boundary, forming mature mRNA lacking exon 7 [Shimmoto et al., 1990, 
1993].   
Next, we established a model system mimicking the CTSA gene 
harboring the IVS7 +3a>g mutation.  For this purpose, we chose to use 
HeLa cells, because this cell line is often used for splicing analysis 
with mini genes and produces the correctly spliced mRNA from the 
endogenous CTSA gene (Fig. 1B).  As for the mini gene, we first prepared 
small mini gene plasmids carrying just exon 6 to exon 8 of the wild-type 
CTSA gene and one having the mutation (see Fig. 1C).  As shown in Fig. 
1D, when HeLa cells were transfected with mutant CTSA mini gene plasmid, 
we observed no signal corresponding to the RNA containing exon 7 (“exons 
6-8”).  When HeLa cells were transfected with wild-type CTSA mini gene 
plasmid, we observed a weak signal corresponding to the RNA containing 
exon 7.  These results indicate that introduction of mini gene plasmids 
encoding the nucleotide sequence from exon 6 to exon 8 was not suitable 
to mimic splicing properties of wild-type and mutant CTSA gene.   
Thus, we next prepared much longer mini gene plasmids carrying 
exon 3 to exon 11 of the wild-type CTSA gene and its mutant.  When HeLa 
cells were transfected with these plasmids and examined for the expressed 
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RNA species, this system was found to be much better; i.e., cells 
transfected with the mini gene plasmid carrying the mutation only showed 
the signal corresponding to the RNA lacking exon 7 (“exon 6 and exon 
8”), and those with the wild-type mini gene plasmid showed a strong signal 
corresponding to the RNA containing exon 7.  Although the ratio of exon 
7 inclusion in cells introduced with the wild-type mini gene plasmid 
containing exon 3 to exon 11 varied in different transfection experiments, 
it was always significantly higher than that obtained in the case of 
the wild-type mini gene plasmid containing exon 6 to exon 8.  This result 
was not surprising, because the use of mini genes was reported not always 
to reflect the splicing pattern of the endogenous gene, probably due 
to lack of the necessary genomic sequence context [Baralle et al., 2006; 
Sánchez-Alcudia et al., 2011].  This finding suggests that splicing of 
intron 7 of CTSA was influenced not only by the proximal but also the 
distal region of the gene.  Based on these observations, we concluded 
that the second mini gene plasmid, i.e., the one carrying exon 3 to exon 
11 of the IVS7 +3a>g mutation, would be more suitable for evaluation 
of the effects of modified U1 snRNAs.   
It should be noted that we often observed an extra signal of 
amplified DNA band (designated as “X” in Fig. 1D) between two DNA bands 
of “exons 6–8” and “exon 6 and exon 8”.  We considered the possibility 
that there was an RT-PCR product having an insertion of “gt” nucleotides 
between exon 6 and exon 8 (this product is designated as “exon 6-gt-exon 
8”) and that this band “X” might contain heteroduplex DNA comprising 
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the “exon 6 and exon 8” and “exon 6–gt-exon 8”.  Detailed 
characterization of band “X” is summarized in Supplemental results, Fig. 
S2A, B, C, and D.  
 
3.2. Screening of modified U1 snRNA effective for proper splicing of 
pre-mRNA encoded by the human CTSA gene having the IVS7 +3a>g mutation 
In silico analysis using splice site prediction programs 
suggested that the splicing score is slightly decreased by IVS7 +3a>g 
mutation (from 89.26 to 88.10 according to Human Splicing Finder; from 
9.99 to 6.34 according to MaxEntScan; and from 0.95 to 0.57 according 
to NNSPLICE 0.9).  Although the IVS7 +3a>g mutation shows only 1 base 
substitution, there is a possibility that the wild-type U1 snRNA becomes 
incapable of associating with the pre-mRNA having the IVS7 +3a>g mutation, 
and thus exon 7 is skipped.  Thus, to enable the formation of RNA/RNA 
hybrids between U1 snRNA and 5’-ss of intron 7, we first expected that 
the 6th uracil base of U1 snRNA, which should form a base pair with mutated 
guanine base at the 5’-ss of intron 7, should be reversely mutated to 
a cytosine base (hereafter, this modified U1 snRNA is referred to as 
6th U>C; Fig. 2A, upper panel).  To examine the effectiveness of this 
modified U1 snRNA (6th U>C) for rescue from the splice defect, we prepared 
the expression plasmid of this U1 snRNA.  Then, HeLa cells were 
transfected with plasmids encoding exon 3 to exon 11 of mutant CTSA mini 
gene and those encoding modified U1 snRNA (6th U>C).  After harvesting 
of the cells, expressed RNA was analyzed by RT-PCR.  However, this 
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modification was not effective for rescue from the splice defect (Fig. 
2A, lower panel). 
Based on the above result, we thought that a much stronger 
interaction between U1 snRNA and 5’-ss would be required for rescue from 
the splice defect caused by the mutation.  Thus, we designed a modified 
U1 snRNA, referred to as modified-1, having a nucleotide sequence 
completely complementary to that of the mutated 5’-ss (Fig. 2B, upper 
panel).  As a result, this modified-1 showed a moderate rescue (Fig. 
2B, lower panel).  Next, we sought the mostly effective modified U1 snRNA 
by serial substitution of the nucleotide.  The 5’-nucleotide of the 
modified-1, i.e., U base, was serially substituted with another 
nucleotide (Fig. 2B, upper panel).  When we examined the effectiveness 
of these modified U1 snRNAs (modified-1, -2, -3, and -4) in rescuing 
cells from the splice defect, modified-4 was found to be the most 
effective (Fig. 2B, lower panel).  Then, by fixing the first nucleotide 
as “A”, the second nucleotide was serially substituted (modified-4, -5, 
-6, and -7).  Likewise, after optimization of the second nucleotide, 
the third nucleotide was also serially substituted (modified-7, -8, -9, 
and -10).  From the band intensity, exon 7 inclusion was evaluated as 
shown in Fig. 2C.  By performing these nucleotide substitution studies, 
we found that all modified U1 snRNAs except for 6th U>C increased the 
exon 7 inclusion; and modified-7 U1 snRNA was shown to have the relatively 
highest activity in rescuing the splice defect caused by the IVS7 +3a>g 
mutation.  The dose dependency of the modified-7 U1 expression plasmid 
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was determined as shown in Fig. 2D.  Experimentally, it was difficult 
to distinguish wild-type U1 snRNA (endogenous) and modified-7 U1 snRNA, 
because their nucleotide sequences were completely the same except for 
only 3 bases at their 5’-end; and also the expression level of endogenous 
U1 snRNA would be much higher than that of modified-7 U1 snRNA.  Therefore, 
at this stage, we did not check the expression level of modified-7 U1 
snRNA and did not estimate the ratio of wild-type U1 snRNA and modified-7 
U1 snRNA and that of modified-7 U1 snRNA and pre-mRNA transcribed from 
the CTSA mini gene plasmid.  However, the amount of properly spliced 
mRNA was shown to increase in accordance with the amount of modified-7 
U1 expression plasmid transfected into the cells (Fig. 2D).  Detailed 
characterizations, including the effect on exon 7 splicing of the 
wild-type CTSA gene, of the modified-7 U1 expression plasmid are shown 
in Supplemental results, Fig. S3A, B, C, and D.   
 
3.3. Modified U1 snRNA was also effective for the synthesis of the 
corresponding protein 
We further examined whether the rescue effect of modified-7 U1 
snRNA could be also observed at the level of protein expression.  The 
CTSA mini gene plasmid that we used was designed to be applicable for 
studies on protein synthesis; i.e., the 5’ and 3’-ends of the nucleotide 
sequence of mini gene were flanked with nucleotide sequences encoding 
EGFP and c-Myc tag, respectively (see Fig. 1C).  If the nucleotide 
sequences corresponding to exons 3-11 of CTSA gene were properly spliced, 
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the transcript formed would code for a 63-kilodaltons (kDa) protein 
composed of EGFP, the part of CTSA encoded by exon 3 to exon 11, and 
c-Myc tag (for detailed amino acid sequences, see Supplemental results, 
Fig. S1D).  As exon 7 contains 92 nucleotides (Supplemental results, 
Fig. S1C), skipping of exon 7 causes a frame shift and the stop codon 
arises by another frame in exon 8.  In this case, a 45-kDa protein without 
the Myc tag was produced.   
To examine whether the modified-7 U1 snRNA would be effective 
for formation of this ideal protein, we used COS7 cells because of their 
high protein expression from pcDNA3.1 plasmid.  COS7 cells were 
transfected with CTSA mini gene plasmid and U1 plasmid, and then cell 
lysates were prepared and subjected to immunodetection.  As shown in 
Fig. 3, when COS7 cells were transfected with the wild-type CTSA mini 
gene plasmid and wild-type U1 plasmid, a 63-kDa protein (shown by arrow) 
was detected by both anti-EGFP and anti-Myc antibodies.  This protein 
was not detected when mutant CTSA mini gene plasmid and wild-type U1 
plasmid were used.  On the other hand, when the cells were transfected 
with mutant CTSA mini gene plasmid and modified-7 U1 plasmid, the 63-kDa 
protein was detected by both antibodies.  The observed differences in 
the expression levels of EGFP-CTSA-Myc protein among these samples did 
not reflect the differences in the transfection efficiency of COS7 cells, 
because the expression levels of EGFP (27-kDa), co-transfected to 
estimate the transfection efficiency, were almost the same among the 
samples (Fig. 3, 27-kDa EGFP).  Based on these results, we concluded 
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that the modified-7 U1 snRNA designed in the present study was not only 
effective for proper splicing of the mRNA coded by the CTSA gene having 
the IVS7 +3a>g mutation, but also for the synthesis of the target protein.   
The smaller protein observed in both EGFP and Myc panels for cells 
transfected with the mini gene plasmid (shown by broken arrows) might 
have been translated from a splice variant.  Although we could not 
identify the corresponding transcript, a possible explanation about this 
protein is given in Supplemental results, Fig. S2D. 
 
4. Discussion 
For the correct pre-mRNA splicing, the 5’-ss, the 3’-ss including 
the polypyrimidine tract, the branch point located upstream of the 3’-ss, 
and intronic and/or exonic splice regulatory elements are required.  
Generally, the base pairing between U1 snRNA and the 5’-ss of pre-mRNA 
is necessary for the initiation of the splicing reaction, although 
U1-independent pre-mRNA splicing has been reported [Lund and Kjems, 
2002; Fukumura et al., 2009].  For initiation of the splicing reaction, 
the 5’-end of U1 snRNA, 11 bases as maximum, interacts with the 5’-ss 
of pre-mRNA by making base pairs [Roca et al., 2013].  Because the 
nucleotides at positions +7 and +8 of the 5’-ss are not consistently 
conserved in human genes, the 9 bases from -3 to +6 of the 5’-ss (consensus 
sequence of 5’-MAG/GURAGU) are generally recognized by complementary 
bases from the third to eleventh position of U1 snRNA.  However, if the 
degree of complementation is decreased by mutation at the 5’-ss, U1 snRNA 
19 
 
may not properly anneal with the pre-mRNA, thus causing a splice defect.   
In the case of the human CTSA gene, the adenine to guanine base 
substitution at the +3 position of intron 7 (IVS7 +3a>g) causes skipping 
of exon 7 in its mRNA.  Both nucleotides adenine and guanine at the +3 
position match the consensus nucleotide sequence of 5’-ss; and, hence, 
the nucleotide substitution from adenine to guanine seemed not to 
influence the splicing reaction.  However, this substitution caused a 
splice defect (Fig. 1D).  Similarly, a splice defect due to nucleotide 
substitution of adenine for guanine at the +3 position has been reported 
to occur in several genes [Ohno et al., 1999; Madsen et al., 2006; Le 
Guédard-Méreuze et al., 2009; Sánchez-Alcudia et al., 2011]; and the 
relationship between the nucleotide sequence of this region and degree 
of splice defect may be summarized as follows [Ohno et al., 1999]: In 
the 5’-ss having the guanine at the +3 position, but showing proper 
splicing, there tends to be a consensus sequence at +4 to +6.  Inversely, 
in the 5’-ss having the guanine at the +3 position, and showing the splice 
defect, there tends to be a non-consensus sequence at +4 to +6.  In the 
case of the 5’-ss of intron 7 of the human CTSA gene, nucleotides from 
+4 to +6 (or +4 to +8) also showed a poor association with the wild-type 
U1 snRNA, as was depicted in Fig. 1A.  There is no evidence, but we think 
that the long intron caused by the skipping of exon 7 does not have any 
physiological role and that it is degraded as an ordinary intron.  
To rescue the splice defect due to mutation at the 5’-ss, trials 
using modified U1 snRNA have been reported for some diseases.  Therefore, 
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we examined the effect of modified U1 snRNA on the splicing of pre-mRNA 
encoded by the CTSA gene having the IVS7 +3a>g mutation.  All modified 
U1 snRNAs, except for the 6th U>C, were effective in proper splicing 
of pre-mRNA encoded by the gene having the mutation (Fig. 2C).  At this 
stage, the reasons causing the difference in the proper splicing effects 
among the modified U1 snRNAs remain uncertain.  Because exon 7 inclusion 
was not completely achieved in the cells transfected with a mini gene 
even if it was a wild-type one (Fig. 1D), the estimated effect of modified 
U1 snRNAs on correct splicing might be low.   
For in vivo application for rescue from a splice defect, modified 
U1 snRNA constructed in a plasmid or rAAV vector has been examined by 
using mice having a 5’-ss mutation of the coagulation F7 gene [Balestra 
et al., 2014] and the dopa decarboxylase gene [Lee et al., 2016].  As 
a result, although exon inclusions by modified U1 snRNA were observed, 
an off-target effect by modified U1 snRNA was suggested.  To improve 
specificity and reduce the potential off-target effects, exon-specific 
U1 snRNA (ExSpeU1), targeting non-conserved intronic sequences 
downstream of the 5’-ss, was developed earlier [Fernandez Alanis et al., 
2012].  Intraperitoneal injection of rAAV9 containing an ExSpeU1 
expression unit was shown to increase the amount of mRNA including exon 
7 of the survival motor neuron 2 gene in brain, heart, kidney, liver, 
and skeletal muscle of transgenic mice [Dal Mas et al., 2015].  As 
galactosialidosis is a condition that affects many areas of the body 
including the brain, systemic rAAV-mediated gene delivery for modified 
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U1 snRNA or ExSpeU1 could be effective for treatment of galactosialidosis 
caused by the CTSA gene harboring the IVS7 +3a>g mutation.   
In cells derived from galactosialidosis patients who were 
homozygous for the IVS7 +3a>g CTSA gene allele, CTSA enzyme activity 
was not detected [Shimmoto et al., 1993].  In some lysosomal storage 
diseases, it was suggested that 2–10% of normal enzyme activity was 
required to rescue cells from the metabolic defects [Hu et al., 2012].  
In our present study, although we did not examine the recovery of the 
enzyme activity, the expression of appropriate protein synthesized from 
the mutant mini gene plasmid was apparently observed when the modified 
U1 snRNA was used.  To investigate whether modified U1 snRNA could be 
a potential medicinal tool for the treatment of galactosialidosis caused 
by the CTSA gene harboring the IVS7 +3a>g mutation, further analysis 
using patient-derived cells and animal models are necessary.  
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Figure legends 
Fig. 1. The nucleotide sequences of U1 snRNA and 5’-ss of the 7th intron 
of pre-mRNA encoding CTSA and RT-PCR analysis of the CTSA transcript  
(A) Manner of interaction between the nucleotide sequences of 
U1 snRNA and 5’-ss of the 7th intron of pre-mRNA encoding CTSA.  The 
nucleotide position corresponding to the IVS7 +3a>g mutation is 
indicated by the asterisk.  The 5’-end of U1 snRNA shown with lowercase 
letters fails to base pair with those in the pre-mRNA of CTSA having 
the mutation.  
(B) RT-PCR of the CTSA transcript in human normal cells.  RNA 
samples of human liver and HeLa cells were reversely transcribed; then, 
the nucleotide sequence corresponding to the regions of exon 6 to exon 
8 was amplified by PCR with primer 6 and primer 8.  The DNA band strongly 
stained by ethidium bromide contained the nucleotide sequence composed 
of “exons 6-8” (350 base pairs [bp]).  The position of the expected 
migration of the DNA band containing the nucleotide sequence composed 
of “exon 6 and exon 8” (258 bp) is also shown. 
(C) Structures of the mini gene plasmids encoding the regions 
of “exon 6 to exon 8” or “exon 3 to exon 11” of human CTSA gene, harboring 
the IVS7 +3a>g mutation (shown by asterisks).  The plasmids of these 
regions of the wild-type CTSA gene were also prepared and used for the 
control experiment.  Primers (T7 primer, BGH pA primer, primer 6, and 
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primer 8) used for specific RT-PCR of transcripts from the mini gene 
plasmids are also shown. 
(D) RT-PCR of the CTSA transcript from the mini genes.  HeLa cells 
were transfected with one of these 4 mini gene plasmids.  The RNA samples 
from cells were reverse transcribed, and the cDNAs thus prepared were 
amplified by using T7 primer and BGH pA primer; and then DNA fragments 
containing the region between exon 6 and exon 8 were re-amplified with 
primer 6 and primer 8 (note that the PCR was designed not to amplify 
the transcript encoded by the endogenous CTSA gene).  Upper and lower 
bands represent DNA fragments containing “exons 6-8 (350 bp)” and “exon 
6 and exon 8 (258 bp)”, respectively.  As for band “X”, see Supplemental 
results, Fig. S2A, B, C, and D. 
 
Fig. 2. Effects of modified U1 snRNAs on rescue from the splice defect 
at 5’-ss of the CTSA gene having the IVS7 +3a>g mutation 
Panels A and B show the results of the 6th U>C (A) and serial 
mutation analysis (B), respectively.  In the upper panel, the nucleotide 
sequences of the 5’-end of the U1 snRNAs used in this experiment and 
5’-ss of IVS7 +3a>g CTSA pre-mRNA are shown.  The IVS7 +3a>g mutation 
is indicated with an asterisk.  In the 5’-end of U1 snRNA, nucleotides 
shown by uppercase or lowercase letters indicate those complementary 
or non-complementary, respectively, to the nucleotide sequence of the 
IVS7 +3a>g allele.  In the lower panel, the results of the analysis of 
the RNA species are shown.  HeLa cells were co-transfected with the mini 
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gene plasmid (exons 3-11, mutant) and U1 plasmid, and then RNA samples 
were analyzed by RT-PCR.  In the case of products obtained by using 
modified-7 U1 snRNA, the DNA fragment containing the upper band (“exons 
6-8”) was purified from the electrophoretic gel, and the exon boundaries 
(exon 6/exon 7 and exon 7/exon 8) were confirmed by direct sequencing 
(data not shown).   
(C) Histograms indicate the percentage of exon 7 inclusion upon 
densitometric analysis of the bands.  The band intensities of “exons 
6-8”, “X”, and “exon 6 and exon 8” were calculated from the 
electrophoretic gel; and total band intensity was obtained as sum of 
those of 3 bands.  The percentage of the band intensity of “exons 6-8” 
is expressed as the mean ± SD from 4 independent experiments except for 
control-1 and -2 (3 independent experiments).  As for the control-1 and 
-2, the RNA samples were prepared from cells transfected with only mini 
gene plasmid (exons 3-11, wild-type) and both mini gene plasmid (exons 
3-11, wild-type) and wild-type U1 plasmid, respectively.  The 
electrophoregrams of control-1 and -2 are shown in Fig. 1D (control-1) 
and Supplemental results, Fig. S3D (control-1 and -2).   
(D) Dose dependency of modified-7 U1 expression plasmid for 
splicing was examined.  The mini gene plasmid (exons 3-11, mutant) and 
U1 plasmid (wild-type and/or modified-7) were introduced into HeLa cells 
at the indicated amounts (μg).  The percentage of exon 7 inclusion is 
indicated below each lane, expressed as the mean ± SD from 3 independent 
experiments. 
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Fig. 3. Immunodetection of EFGP-CTSA-Myc fusion protein expressed in 
COS7 cells 
COS7 cells were transfected with i) pcDNA3.1/Hygro(-) plasmid 
(empty vector) or CTSA mini gene plasmid, ii) U1 plasmid, and iii) EGFP 
expression plasmid (for estimation of transfection efficiencies).  
After harvesting, cell lysates were subjected to SDS-PAGE and subsequent 
Western blotting using anti-EGFP and anti-Myc antibodies.  Two 
independently prepared samples were subjected to the analyses.  Upper 
and middle photos show EFGP-CTSA-Myc fusion protein (approx. 63-kDa) 
detected by anti-EGFP antibody and by anti-Myc antibody, respectively 
(shown by arrows).  Bottom photo represents the expression level of the 
27-kDa EGFP (not fused with another peptide) as a transfection control.  
As for the smaller protein shown by the broken arrows, see Supplemental 
results, Fig. S2D. 
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Highlights 
1.  Model system with a mini gene reproduced exon 7 skipping by IVS7 
+3a>g of CTSA gene.   
2.  One base substitution of U1 snRNA for +3a>g was not effective for 
proper splicing. 
3.  Increased complementarity of U1 snRNA to splice site produced 
properly spliced mRNA. 
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Supplemental methods 
1. Construction of expression plasmids of wild-type and modified U1 
snRNAs 
To construct the expression plasmid of human U1 snRNA, we 
amplified human genomic DNA by PCR using PrimeSTAR HS DNA Polymerase 
(TaKaRa, Otsu, Japan).  For amplification from its own promoter to 
transcription termination signal (from -393 to +199), the primer pair 
of 5’-aaaggatccTAAGGACCAGCTTCTTTGGGAGAGAACAGAC (sense) and 
5’-aaagtcgacTTAGCGTACAGTCTACTTTTGAAACTCCAG (antisense) was used 
(nucleotides artificially added for restriction sites [BamHI and SalI] 
and for efficient digestion are shown by the lowercase letters).  The 
obtained DNA fragment was digested with BamHI and SalI, and subcloned 
into these restriction sites of pUC19.  This plasmid is referred to as 
wild-type U1 plasmid.   
By PCR using mutated oligonucleotide primers and the wild-type 
U1 plasmid, the coding regions for modified U1 snRNAs were prepared.  
The obtained PCR product was digested with BglII (position -7) and SalI 
(artificially added to the 3’-end of U1 snRNA gene).  To construct the 
expression plasmid of modified U1 snRNA, the corresponding region of 
the wild-type U1 plasmid was substituted with the thus prepared mutated 
DNA fragment.   
 
2. Construction of wild-type CTSA mini gene plasmids 
To construct the mini gene plasmids of human CTSA from exon 6 
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to exon 8 and from exon 3 to exon 11, we amplified human genomic DNA 
by PCR using PrimeSTAR HS DNA Polymerase.  For amplification from exon 
6 to exon 8, 5’-gcactcgaGTCGCCCAGAGCAATTTTGAGGCCCTTCAAG (primer 6, 
sense) and 5’-gcagtcgacATTGGTCACGCATTCCAGGTCTTTGTTGTC (primer 8, 
antisense) were used; and for that from exon 3 to exon 11, 
5’-gcatggtactctcgagcgtgGTTTGTGGAGTCCCAGAAGGATCCC (primer 3, sense) 
and 5’-gcatggtacttagtcgacgTTGCACATGTCCCATTGTGGCAGCTG (primer 11, 
antisense) were employed.  Nucleotides artificially added for 
restriction sites (XhoI and SalI) and for efficient digestion are shown 
by lowercase letters.  The obtained DNA fragment was digested with XhoI 
and SalI and subcloned into pcDNA3.1/Hygro(-), in which DNA fragment 
encoding CTSA was sandwiched between those fragments encoding EGFP and 
c-Myc tag.  These mini gene plasmids are referred to as wild-type CTSA 
mini gene plasmids (“exons 6-8” or “exons 3-11”). 
 
3. RT-PCR 
A 1-μg aliquot of total RNA from HeLa cells was reversely 
transcribed with oligo(dT) primer.  ss-cDNA corresponding to 50 ng of 
total RNA was first amplified by 35 cycles of PCR with T7 primer and 
BGH pA primer in a 25-μL reaction mixture using Ex Taq Hot Start Version 
(TaKaRa).  The reaction conditions for 1 cycle of PCR were 94 °C for 
0.5 min, 56 °C for 0.5 min, and 72 °C for 1.5 min.  Approx. 1.7-1.8 kbp 
products were obtained by this PCR.  Then, the reaction mixture was 
diluted 5,000–10,000 times with distilled water, and a 1-μL aliquot of 
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diluted mixture was amplified by 20 cycles of PCR with primer 6 and primer 
8 in a 25-μL reaction mixture.  The reaction conditions for 1 cycle of 
PCR were 94 °C for 0.5 min, 56 °C for 0.5 min, and 72 °C for 0.5 min.  
The reaction mixtures were then subjected to PAGE. 
Transcript from cells without transfection of mini gene plasmids 
was analyzed by 1 round of PCR with primer 6 and primer 8.  Briefly, 
samples of poly(A)+ RNA of human liver and total RNA of HeLa cells were 
reversely transcribed with oligo(dT) primer.  Samples of ss-cDNA 
corresponding to 5 ng (liver) and 50 ng (HeLa cells) of RNA were amplified 
by 35 cycles of PCR with primer 6 and primer 8 in a 25-μL reaction mixture 
using Ex Taq Hot Start Version.  The reaction conditions for 1 cycle 
of PCR were 94 °C for 0.5 min, 56 °C for 0.5 min, and 72 °C for 0.5 min.   
 
Supplemental results 
Fig. S1. Structures of the CTSA mini gene plasmid and nucleotide sequence 
(A) The overall structure of CTSA mini gene plasmids (“exons 6-8” 
and “exons 3-11”) is depicted.  Asterisk indicates the IVS7 +3a>g 
mutation.   
(B) The nucleotide sequences (upper line) and amino acid sequences 
(lower line) of EGFP and c-Myc tag coding regions are shown.  The 
underlined nucleotides indicate artificially added nucleotides to 
create a restriction site(s) and a termination codon.  The amino acids 
are shown by the one-letter abbreviation code, and underlined amino acids 
represent those encoded by artificially added nucleotides. 
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(C) The nucleotide sequence (upper line) and amino acid sequence 
(lower line) of the CTSA gene from exon 3 to exon 11 are shown.  
Nucleotides in the exon and intron are shown by uppercase and lowercase 
letters, respectively.  The asterisk at the exon 7/intron 7 boundary 
indicates the IVS7 +3a>g mutation.  In both lines, underlined 
nucleotides and amino acids indicate those as described in “B”. 
(D) Amino acid sequence of the EGFP-CTSA-Myc fusion protein 
produced by transfection with the CTSA mini gene plasmid (exons 3-11).  
The amino acids coded by additional nucleotides containing restriction 
sites are underlined as described in “B”.  When pre-mRNAs transcribed 
from the CTSA mini gene plasmids (exons 3-11) were properly spliced, 
an approx. 63-kDa protein (total of 557 amino acids) was produced.   
 
Fig. S2. Characterization of the band “X” obtained by RT-PCR 
(A) The nucleotide sequence of the cDNA corresponding to exon 
6 to exon 8 of CTSA mRNA is shown.  Boxes above nucleotides show exons 
(exon 6, 7, and 8).  Arrows indicate oligonucleotide primers (primer 
6, primer 8, primer F, and primer R) used in this experiment.  Primer 
F and primer R were used in “C” and “D”. 
(B) RT-PCR products were obtained with T7 primer and BGH pA primer 
(1st PCR) and primer 6 and primer 8 (2nd PCR).  The reaction mixture 
of RT-PCR was loaded onto a polyacrylamide gel and stained with ethidium 
bromide (lane 1).  DNA in band “X” was carefully extracted from the 
electrophoretic gel.  In addition, DNAs in band “exons 6-8 (350 bp)” 
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and “exon 6 and exon 8 (258 bp)” were also purified.  After purification, 
DNAs from “exons 6-8”, from “X”, and from “exon 6 and exon 8” were loaded 
(lane 2, 3, and 4, respectively).   
(C) The DNA molecules contained in band “X” (lane 3 in “B”) was 
directly sequenced using primer F.  The sequencing peak showed the 
nucleotide sequences following exon 6 of the PCR products in band “X”.  
As a result, band “X” appeared to contain mainly 2 DNA species, i) a 
DNA fragment of exon 6 directly connected to exon 8, and ii) a DNA fragment 
having an insertion of “gt” nucleotides between exon 6 and exon 8 
(hereafter, this latter DNA is designated as “exon 6-gt-exon 8”).  DNAs 
contained in band of “exons 6-8” (lane 2 in “B”) and “exon 6 and exon 
8” (lane 4 in “B”) were also sequenced.  DNA in band of “exons 6-8” was 
confirmed to have the expected nucleotide sequence.  Whereas, in the 
case of the “exon 6 and exon 8” band, DNA in which exon 6 was directly 
connected to exon 8, was shown to be the main component.  In addition, 
although we could not identify the nucleotide sequence, there was other 
DNA in which exon 6 was not directly connected to exon 8 (data not shown).  
(D) To further characterize the DNA species in bands observed 
in “B”, we re-amplified gel-purified DNAs by using the primer pair of 
primer F and primer R.  After PCR, the reaction mixtures were loaded 
onto a polyacrylamide gel.  When the RT-PCR mixture (lane 1 in “B”) was 
used as a template, 3 bands were observed.  From their electrophoretic 
mobility, it seemed that DNAs in bands “a (262 bp)”, “b”, and “c (170 
bp)” had arisen from “exons 6-8”, “X”, and “exon 6 and exon 8”, 
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respectively.  When purified DNA from lane 2 in “B” (“exons 6-8”) was 
used as a template, only band “a” was observed.  On the contrary, when 
purified DNA from lane 4 in “B” (“exon 6 and exon 8”) was used as a template, 
2 bands, band “b” and band “c”, were observed.  A similar band pattern 
was also observed when DNA from lane 3 in “B” (“X”) was used as a template.   
These observations suggest that the DNA of band “X” was a 
heteroduplex comprising the “exon 6 and exon 8” and “exon 6–gt-exon 8”.  
Moreover, if a splice variant including “exon 6-gt-exon 8” existed, a 
59-kDa protein (total of 527 amino acids) with EGFP and Myc tag would 
be synthesized from a mini gene plasmid containing exons 3-11.  
Accordingly, the smaller protein shown by the broken arrows in Fig. 3 
(observed in both EGFP and Myc panels) might have been translated from 
this splice variant. 
 
Fig. S3. Detailed analysis of modified-7 U1 expression plasmid 
The experiments in this section were conducted to ascertain that 
the splicing correction was achieved by “U1 snRNA molecule” expressed 
from modified U1 plasmid (A, B, and C). In addition, the effect on exon 
7 inclusion of wild-type CTSA gene by modified U1 snRNA was examined 
(D).   
(A) The structures of the expression plasmid of U1 snRNA lacking 
its promoter (∆Pro and RevPro) are depicted.  For construction of these 
plasmids, the promoter region of the expression plasmids of modified-7 
U1 snRNA was digested with BamHI and BglII.  After elimination of the 
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promoter region, self-ligation was done to make the promoter-less 
plasmid (∆Pro).  To make a plasmid having a promoter region with its 
direction reversed (RevPro), we inserted the digested promoter region 
in the reverse direction. 
(B) Mutations of loop1 and Sm domain of U1 snRNA are shown.  Loop1 
and the Sm domain of U1 snRNA are necessary for U1 snRNA function [Surowy 
et al., 1989; Hamm et al., 1990; Hamm and Mattaj, 1990; Gunderson et 
al., 1998] and substitution of cytosine to adenine at 33 (C33A) was 
reported to not have any influence on its function [Surowy et al., 1989].  
By use of the overlap extension PCR method using mutated oligonucleotide 
primers, modified-7 U1 expression plasmid was further modified to create 
expression plasmids of ∆Loop1, ∆Sm, and C33A.  Lowercase letters mean 
that they were substituted from the wild-type U1 snRNA sequences. 
(C) The results of the analysis of RNA species are shown.  
Transfection with the plasmids and RT-PCR experiments were performed 
as described in Fig. 2A and 2B.  Transfection with either ∆Pro or RevPro 
of modified-7 U1 expression plasmids was not effective in rescue from 
the splice defect.  ∆Loop1 and ∆Sm mutants were also not effective, but 
C33A of the modified-7 U1 expression plasmid showed activity similar 
to that of the parental modified-7.  These results showed that the 
modified-7 U1 expression plasmid was transcribed in HeLa and COS7 cells 
and that U1 snRNA synthesized in the cells acted as a splicing factor. 
(D) The effect of modified-7 U1 snRNA on exon 7 inclusion of the 
wild-type CTSA gene was examined.  In the left panel, HeLa cells were 
8 
 
transfected with a 2-μg aliquot of U1 plasmid without the mini gene 
plasmid.  In the right panel, HeLa cells were transfected with a 2-μg 
aliquot of U1 plasmid and a 1-μg aliquot of the CTSA mini gene plasmid 
(exons 3-11, wild-type).  In both panels, the lanes represented as “non” 
mean that RNA samples were prepared from cells without transfection with 
the U1 plasmid.  RT-PCR experiments were performed as described in Fig. 
1D (without mini gene plasmid) and Fig. 2A and 2B (with mini gene plasmid).  
The percentages of exon 7 inclusion are indicated below each lane, 
expressed as the mean ± SD from 3 independent experiments.  As a result, 
modified-7 U1 snRNA was shown to have no effect on the splicing of intron 
7 of the wild-type CTSA gene.   
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